<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03801590</url>
  </required_header>
  <id_info>
    <org_study_id>infectious keratitis</org_study_id>
    <nct_id>NCT03801590</nct_id>
  </id_info>
  <brief_title>Crosslinking in Infectious Keratitis</brief_title>
  <official_title>Safety and Efficacy Of Corneal Collagen Crosslinking (CXL) In Infectious Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microbial keratitis is an infection of the cornea that is associated with risk of permanent&#xD;
      visual impairment.&#xD;
&#xD;
      It can be caused by bacteria, virus, fungus, protozoa and parasites. The common risk factors&#xD;
      for infectious keratitis include ocular trauma, contact lens wear, recent ocular surgery,&#xD;
      preexisting ocular surface disease, dry eyes, lid deformity, corneal sensation impairment,&#xD;
      chronic use of topical steroids and systemic immunosuppression .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The spectrum of bacterial keratitis can also be influenced by geographic and climatic&#xD;
      factors.&#xD;
&#xD;
      The treatment usually consist of Topical administered antibiotics .the emergence of&#xD;
      multidrug-resistant bacteria is a concern that might complicate the treatment and cure of&#xD;
      infectious keratitis.&#xD;
&#xD;
      Collagen cross linking (CXL) using ultraviolet-A (UV-A) and riboflavin in a treatment that&#xD;
      was developed to increase the biochemical strength of the cornea The procedure is based on&#xD;
      using riboflavin as a photosensitizer, which generates reactive oxygen species when activated&#xD;
      by UV-A at 365 or370 nm.&#xD;
&#xD;
      The standard technique (epi-off) also called Dresden Protocol includes removal of the&#xD;
      epithelium in order to expose the underlying stroma to riboflavin, which is otherwise&#xD;
      incompletely absorbed by the epithelium because of tight junctions. The area of corneal&#xD;
      epithelium removed has a diameter of 6.0 to 8.5 mm. A crosslinking procedure without&#xD;
      epithelial removal could also be performed (epi-on). It would likely be less painful compared&#xD;
      to the standard procedure.&#xD;
&#xD;
      The crosslinking process generates reactive oxygen species that can damage the cell walls of&#xD;
      pathogens. CXL induces formation of new covalent bonds thereby rendering the corneal stroma&#xD;
      biomechanically stronger and more resistant to enzymatic digestion . This can potentially&#xD;
      limit the spread of infection. Furthermore, CXL-induced apoptosis could contribute to the&#xD;
      reduction of inflammatory response during corneal infection .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the duration for corneal ulcer healing</measure>
    <time_frame>one year</time_frame>
    <description>By follow up with photography before crosslinking and one week after performing cxl.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Infectious Keratitis</condition>
  <arm_group>
    <arm_group_label>CXL on patients with infectious keratitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea will be carried out on twenty patients with infectious keratitis .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Crosslinking with Riboflavin and UV-A</intervention_name>
    <description>the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.</description>
    <arm_group_label>CXL on patients with infectious keratitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with proved bacterial, fungal, acanthamoeba microbial keratitis .&#xD;
&#xD;
          -  Patient willing to comply with all study procedures .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe corneal scarring or opacification .&#xD;
&#xD;
          -  Patients with viral infectious keratitis&#xD;
&#xD;
          -  Prior herpetic infections .&#xD;
&#xD;
          -  Patients with any coexisting ocular pathology,ocular surface disease .&#xD;
&#xD;
          -  Patients with Autoimmune disease.&#xD;
&#xD;
          -  Pregnant women .&#xD;
&#xD;
          -  Corneal Thickness of less than 400 microns .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008 Jan;27(1):22-7. doi: 10.1097/ICO.0b013e318156caf2.</citation>
    <PMID>18245962</PMID>
  </reference>
  <reference>
    <citation>Jankov Ii MR, Jovanovic V, Nikolic L, Lake JC, Kymionis G, Coskunseven E. Corneal collagen cross-linking. Middle East Afr J Ophthalmol. 2010 Jan;17(1):21-7. doi: 10.4103/0974-9233.61213.</citation>
    <PMID>20543933</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 7, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amira Asem</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

